Physician profile
Blake Putman
NPI 1659784338
$2,062.63
in general payments reported to CMS, 2019-2025
25 companies · $340 in 2025
The $340 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $227 · 2020: $231 · 2021: $211 · 2022: $29.59 · 2023: $315 · 2024: $709 · 2025: $340.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,364.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,363.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $409.32 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $373.12 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $249.31 | 2020-2025 | Rexulti |
| Astrazeneca Pharmaceuticals Lp | $178.55 | 2020-2025 | Airsupra, Breztri |
| Glaxosmithkline, LLC. | $154.50 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $98.10 | 2019-2024 | Otezla, Repatha |
| Lilly USA, LLC | $74.20 | 2020-2024 | Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $57.34 | 2023-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $54.81 | 2024-2025 | Caplyta |
| Horizon Therapeutics Plc | $44.20 | 2019-2021 | |
| Lundbeck LLC | $42.43 | 2023-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $40.01 | 2019-2020 | |
| Abbott Laboratories | $36.31 | 2021-2023 | Proclaim |
| Cashflow Solutions, LLC | $33.18 | 2024 | Pcd-52 737a (US) White, Pcd-51 731a (US) - White, Lympha Press Optimal Plus(US) Bt |
| Mylan Specialty L.P. | $31.17 | 2023-2024 | Yupelri |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $26.78 | 2025 | Inspire |
| Braintree Laboratories, INC. | $23.45 | 2020 | |
| Ascensia Diabetes Care US INC. | $21.80 | 2025 | |
| Xeris Pharmaceuticals, INC. | $19.75 | 2024 | Gvoke Hypopen |
| Exact Sciences Corporation | $18.52 | 2025 | Cologuard Collection Kit |
| Pfizer INC. | $18.31 | 2021 | |
| Bioventus LLC | $15.29 | 2024 | Durolane |
| Alkermes, INC. | $14.78 | 2024 | Vivitrol |
| Alnylam Pharmaceuticals INC. | $14.31 | 2023 | Givlaari |
| Merck Sharp & Dohme LLC | $13.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Blake Putman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.